Magnesium stearate
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Magnesium stearate
- DrugBank Accession Number
- DB14077
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 591.244
Monoisotopic: 590.512452626 - Chemical Formula
- C36H70MgO4
- Synonyms
- Dibasic magnesium stearate
- Magnesium distearate
- Magnesium octadecanoate
- Octadecanoic acid, magnesium salt
- Stearic acid, magnesium salt
- External IDs
- SM 1000
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAtracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium stearate. Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium stearate. Botulinum toxin type A The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium stearate. Botulinum toxin type B The risk or severity of adverse effects can be increased when Magnesium stearate is combined with Botulinum toxin type B. Capreomycin The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium stearate. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Daycling Tablet 5 mg/1 Vaginal Istk3 2017-10-24 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Medi Megaton 2080 Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g) Powder Topical Mbg Inc (Korea Institute of Science Development) 2016-10-16 2017-10-16 US Medi Megaton 2080 Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g) Powder Topical Mbg Inc (Korea Institute of Science Development) 2016-10-15 2017-10-15 US SAMTACID Magnesium stearate (200 mg/5ml) + Aluminum hydroxide (200 mg/5ml) + Simethicone (30 mg/5ml) Suspension Samco Farma 2017-03-03 2024-02-14 Indonesia - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Daycling Magnesium stearate (5 mg/1) Tablet Vaginal Istk3 2017-10-24 Not applicable US Medi Megaton 2080 Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g) Powder Topical Mbg Inc (Korea Institute of Science Development) 2016-10-16 2017-10-16 US Medi Megaton 2080 Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g) Powder Topical Mbg Inc (Korea Institute of Science Development) 2016-10-15 2017-10-15 US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 70097M6I30
- CAS number
- 557-04-0
- InChI Key
- HQKMJHAJHXVSDF-UHFFFAOYSA-L
- InChI
- InChI=1S/2C18H36O2.Mg/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;/h2*2-17H2,1H3,(H,19,20);/q;;+2/p-2
- IUPAC Name
- magnesium(2+) dioctadecanoate
- SMILES
- [Mg++].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O
References
- General References
- Not Available
- External Links
- KEGG Drug
- D02189
- ChemSpider
- 10704
- 1310567
- ChEBI
- 9254
- ChEMBL
- CHEMBL2106633
- Wikipedia
- Magnesium_stearate
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Active Not Recruiting Treatment Female Genitourinary Disease / Lower Urinary Tract Symptoms (LUTS) / Nocturia / Overactive Bladder Syndrome (OABS) / Quality of Life (QOL) / Stress Urinary Incontinence (SUI) / Urethral atrophy / Urinary Urge Incontinence (UUI) / Vagina Atrophy / Voiding Disorders 1 somestatus stop reason just information to hide 2 Unknown Status Treatment Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide 1 Completed Supportive Care Stable COPD Patients 1 somestatus stop reason just information to hide 1 Completed Treatment Asthma 1 somestatus stop reason just information to hide 1 Completed Treatment Chronic Obstructive Pulmonary Disease (COPD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Vaginal 5 mg/1 Tablet Oral Powder Topical Suspension - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.13e-05 mg/mL ALOGPS logP 10.89 ALOGPS logP 7.15 Chemaxon logS -7.7 ALOGPS pKa (Strongest Acidic) 4.95 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 40.13 Å2 Chemaxon Rotatable Bond Count 32 Chemaxon Refractivity 97.12 m3·mol-1 Chemaxon Polarizability 38.18 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at June 17, 2018 16:58 / Updated at June 12, 2020 16:53